Levosulpiride

Levosulpiride
Clinical data
Trade namesDislep, Sulpepta, others
Other namesL-Sulpiride; S-(–)-Sulpiride; RV-12309
Routes of
administration		Oral
ATC code
Identifiers
  • N-[[(2S)-1-ethylpyrrolidin-2-yl]methyl]-2-methoxy-5-sulfamoylbenzamide
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC15H23N3O4S
Molar mass341.43 g·mol−1
3D model (JSmol)
  • CCN1CCC[C@H]1CNC(=O)C2=C(C=CC(=C2)S(=O)(=O)N)OC
  • InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
  • Key:BGRJTUBHPOOWDU-NSHDSACASA-N
  (verify)

Levosulpiride, sold under the brand names Dislep and Sulpepta among others, is a dopamine antagonist medication which is used in the treatment of psychotic disorders like schizophrenia, major depressive disorder, nausea and vomiting, and gastroparesis.[1][2][3][4] It is taken by mouth.

It is a selective antagonist of the dopamine D2 receptor and an agonist of the serotonin 5-HT4 receptor.[4][5] Chemically, it is a benzamide and the (S)-(−)-enantiomer of sulpiride.[4]

Levosulpiride is marketed widely throughout the world, including in Europe, South Korea, Latin America, India, and Pakistan.[2] It is not available in the United States or the United Kingdom.[2]

  1. ^ "Levosulpiride". AdisInsight. 24 October 2021. Retrieved 22 October 2024.
  2. ^ a b c "Levosulpiride (International database)". Drugs.com. 6 October 2024. Retrieved 22 October 2024.
  3. ^ Mucci A, Nolfe G, Maj M (February 1995). "Levosulpiride: a review of its clinical use in psychiatry". Pharmacol Res. 31 (2): 95–101. doi:10.1016/1043-6618(95)80053-0. PMID 7596960.
  4. ^ a b c Rossi F, Forgione A (February 1995). "Pharmacotoxicological aspects of levosulpiride". Pharmacol Res. 31 (2): 81–94. doi:10.1016/1043-6618(95)80052-2. PMID 7596959.
  5. ^ Tonini M, De Giorgio R, Spelta V, Bassotti G, Di Nucci A, Anselmi L, Balestra B, De Ponti F (April 2003). "5-HT4 receptors contribute to the motor stimulating effect of levosulpiride in the guinea-pig gastrointestinal tract". Dig Liver Dis. 35 (4): 244–250. doi:10.1016/s1590-8658(03)00061-6. PMID 12801035.